Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06380101 · ClinicalTrials.gov registry record · NA

Evaluating a Nonessential Amino Acid Restriction (NEAAR) Medical Food With Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer (LARC)

A NA study of Rectal Cancer, sponsored by University of South Florida.

Recruiting
Registry status
NA
Development phase
30
Enrollment target
1
Study location

NCT06380101 is a NA study of Rectal Cancer that is actively recruiting participants, run by University of South Florida. The registered enrollment target is 30 participants, below the 3,166-participant average among 70 other Rectal Cancer trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06380101, a NA study of Rectal Cancer, is actively recruiting participants, sponsored by University of South Florida.

RECRUITING
Registry status
NA
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

This clinical study aims to assess feasibility, safety, tolerability, and compliance of a Nonessential Amino Acid Restriction (NEAAR) medical food in adult patients with locally advanced rectal cancer during standard of care short course radiotherapy followed by standard of care chemotherapy.

Conditions Studied

Interventions

  • OTHER NEAAR Medical Food

Study Locations (1)

Florida

  • University of South Florida - Tampa

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2023-09-08
Est. Completion 2027-06
Phase NA

Sponsor

University of South Florida

252 total trials

What the Registry Record Tells You About NCT06380101

The ClinicalTrials.gov registry entry for NCT06380101 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,166-participant average among 70 other Rectal Cancer trials with a reported enrollment target (99% lower). The listed sponsor is University of South Florida, which has 252 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Rectal Cancer appearing as the primary indexed condition, and to 1 intervention - of which NEAAR Medical Food is the first listed.

NCT06380101 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.

Frequently Asked Questions

What is clinical trial NCT06380101 about?

NCT06380101 is a clinical study titled "Evaluating a Nonessential Amino Acid Restriction (NEAAR) Medical Food With Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer (LARC)". This clinical study aims to assess feasibility, safety, tolerability, and compliance of a Nonessential Amino Acid Restriction (NEAAR) medical food in adult patients with locally advanced rectal cancer during standard of care short course radiotherapy followed by standard of care chemotherapy.

What is the current status of trial NCT06380101?

This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2023-09-08. Estimated completion is 2027-06.

What conditions does trial NCT06380101 study?

This clinical trial studies the following conditions: Rectal Cancer.

What interventions are being tested in trial NCT06380101?

The interventions under investigation include: NEAAR Medical Food (OTHER).

Who is sponsoring clinical trial NCT06380101?

This trial is sponsored by University of South Florida, which has 252 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06380101 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Rectal Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.